Xeris Biopharma Holdings (XERS) Cash & Equivalents (2020 - 2026)
Xeris Biopharma Holdings (XERS) posted Cash & Equivalents of $121.75 million for Q2 2026, up 105.4% from $59.29 million a year earlier and up 8.9% from the prior quarter.
Powered by 
Analysis
Xeris Biopharma Holdings (XERS) Cash & Equivalents (2020 - 2026) Analysis & Trends
At the end of FY2025, Xeris Biopharma Holdings' Cash & Equivalents came in at $111.04 million, up 55.0% from FY2024.
- Annual Cash & Equivalents shows a five-year compound annual growth rate of 24.2% (FY2020 to FY2025).
- In prior years, Xeris Biopharma Holdings' Cash & Equivalents was $71.62 million in FY2024 (+6.2%), $67.45 million in FY2023 (-44.7%), $121.97 million in FY2022 (+81.3%) and $67.27 million in FY2021 (+78.9%).
- The Q2 2026 figure stands as the highest quarterly Cash & Equivalents since Q4 2022.
- On a year-over-year basis, Cash & Equivalents has increased in each of the last five quarters, with growth averaging 42.1% over the last eight quarters.
- The strongest year-over-year quarter for Cash & Equivalents in the past five years was Q2 2026, with growth of 105.4%; the weakest was Q2 2023, with a decline of 51.6%.
- According to Business Quant data, Cash & Equivalents for the three prior quarters was $111.75 million (Q1 2026), $111.04 million (Q4 2025) and $91.6 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 8.95 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 20.42 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 6.57 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | 6.85 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 7.62 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 4.89 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 13.99 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | 3.18 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 976.00 Mn |
| 10 | Xeris Biopharma Holdings | 1.58 Bn | 1.14 Bn | 79.59 Mn | 121.75 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 121.75 Mn |
| Mar 31, 2026 | 111.75 Mn |
| Dec 31, 2025 | 111.04 Mn |
| Sep 30, 2025 | 91.60 Mn |
| Jun 30, 2025 | 59.29 Mn |
| Mar 31, 2025 | 58.44 Mn |
| Dec 31, 2024 | 71.62 Mn |
| Sep 30, 2024 | 59.23 Mn |
| Jun 30, 2024 | 57.60 Mn |
| Mar 31, 2024 | 62.69 Mn |
| Dec 31, 2023 | 67.45 Mn |
| Sep 30, 2023 | 46.14 Mn |
| Jun 30, 2023 | 46.17 Mn |
| Mar 31, 2023 | 50.98 Mn |
| Dec 31, 2022 | 121.97 Mn |
| Sep 30, 2022 | 84.11 Mn |
| Jun 30, 2022 | 95.34 Mn |
| Mar 31, 2022 | 103.77 Mn |
| Dec 31, 2021 | 67.27 Mn |
| Sep 30, 2021 | 59.49 Mn |
API Access
Xeris Biopharma Holdings Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=XERS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "XERS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=XERS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();